GLP-1 medicines for teens with obesity: the honest picture
GLP-1 shots like Wegovy and Saxenda are now approved for teens aged 12 and older with obesity, and the STEP TEENS trial is encouraging. But long-term data in still-growing bodies is limited, and family-based lifestyle care stays the foundation. Here is what is approved, what the trials show, and the honest limits.
When a teen carries extra weight that harms health, parents want to know if the new GLP-1 shots can help. The short answer is yes, for the right teen and with the right doctor. Two of these medicines are now approved for teens aged 12 and older with obesity. The trial results are real and encouraging. But teens are not small adults. Their bodies are still growing, their minds are still forming, and the long-term data is still limited. This article walks through what is approved, what the trials showed, and the honest limits. Nothing here is a prescription. Your child's doctor decides what fits your child.
What is approved for teens aged 12 and older
Two GLP-1 medicines are approved in the United States for teens aged 12 and older with obesity, and both are meant to be used with a reduced-calorie diet and more physical activity, never on their own. Wegovy (semaglutide) is a once-weekly shot approved for pediatric patients aged 12 years and older with obesity. Saxenda (liraglutide) is a daily shot approved for pediatric patients aged 12 and older who have obesity and a body weight above 60 kg (about 132 pounds), using BMI cut-offs matched to age and sex. Neither is approved for children under 12, and Saxenda is not approved for teens with type 2 diabetes. The dose is always set by your child's doctor and built up slowly. The right medicine, if any, depends on your child's weight, health, and family history, so this is a decision for a doctor, not a trend.
GLP-1 shots are a safe cosmetic shortcut for teens who want to look thinner.
falseFalse on two counts. These medicines are approved for obesity as a health condition, not for cosmetic weight loss, and only for teens aged 12 and older. The teen trials are encouraging. STEP TEENS showed a 16.1 percent BMI drop with semaglutide over 68 weeks. But long-term data in still-growing teens is limited, with only 5 of 27 pediatric drug trials reporting results beyond 6 months, and family-based lifestyle care remains the foundation. Your child's doctor, not a teen or a trend, decides if medicine fits.
What a careful family does first
The bottom line
GLP-1 medicines can help teens aged 12 and older with obesity, and the STEP TEENS trial makes a real case: semaglutide plus lifestyle cut BMI far more than lifestyle alone. Saxenda is also approved for teens aged 12 and older above 60 kg. But the honest limits matter. The long-term data in still-growing teens is limited, family-based lifestyle care stays the foundation, these shots are for health not for looks, and a teen's mood and growth need watching along the way. The decision belongs to your child's doctor, built on family support, honest goals, and regular follow-up. Nothing here is a prescription. Talk to your child's doctor about your own case.